Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1966873 | Clinica Chimica Acta | 2008 | 4 Pages |
Abstract
IntroductionThe APRI and FIB-4 index are markers that have been proposed for the evaluation of hepatic fibrosis in patients co-infected with HIV and HCV.MethodsWe retrospectively compared these 2 indices in 81 co-infected patients staged by liver biopsy.ResultsThe FIB-4 index was superior to the APRI for the differentiation of mild from significant fibrosis in both predictive values and area under the receiver operator curve (AUROC). The tests were comparable for the differentiation of mild/moderate from advanced fibrosis.ConclusionThese tests could be used to evaluate co-infected patients for treatment, and exclude those that do not need periodic screening for hepatocellular carcinoma.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Tony Trang, John R. Petersen, Ned Snyder,